{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:17:23Z","timestamp":1791440243490,"version":"4.3.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Ozzie Giglio"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite their potential, sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) have not been well-studied in transthyretin amyloid cardiomyopathy (ATTR-CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short-term efficacy and safety of SGLT2i in ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We screened consecutive patients seen at a tertiary care centre and identified 87 ATTR-CM patients treated with SGLT2i and 95 untreated control patients. Endpoints included changes in weight, loop diuretic dose, and cardiac\/renal biomarkers. The median age of the overall population was 79 (interquartile range [IQR] 11) years. Nearly 90% of patients were male, and 93% were on a transthyretin stabilizer. Control patients demonstrated generally less severe disease at baseline compared to SGLT2i-treated patients, with lower median Columbia risk score (p\u2009&amp;lt;\u20090.001). Median follow-up time was 5.6 (IQR 5.2) and 8.4 (IQR 2.1) months in the SGLT2i and control cohorts, respectively. Compared with controls, SGLT2i treatment was associated with significantly greater reductions from baseline in weight, loop diuretic dose, and uric acid during follow-up (p\u2009&amp;lt;\u20090.001). While no significant between-group differences were observed on cardiac biomarkers, estimated glomerular filtration rate was significantly reduced versus controls 1\u2009month after SGLT2i initiation (p\u2009=\u20090.002), but no significant differences were observed at later timepoints. Results were similar in a propensity score-matched analysis (n\u2009=\u200942 per cohort). A total of 10 (11.5%) patients discontinued SGLT2i, most commonly due to genitourinary symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors were well tolerated by most patients with ATTR-CM and appeared to improve volume status and combat diuretic resistance. Randomized studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3198","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:20:02Z","timestamp":1710555602000},"page":"938-947","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety"],"prefix":"10.1093","volume":"26","author":[{"given":"Frederick M.","family":"Lang","sequence":"first","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Teruya","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Weinsaft","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsina Mirabal","family":"Santos","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ani","family":"Nalbandian","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bampatsias","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York-Presbyterian\/Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"2026010913074704400_ejhf3198-bib-0001","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913074704400_ejhf3198-bib-0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0004","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026010913074704400_ejhf3198-bib-0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0006","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"SGLT-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913074704400_ejhf3198-bib-0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0008","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0010","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20\u2009years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026010913074704400_ejhf3198-bib-0011","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913074704400_ejhf3198-bib-0012","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913074704400_ejhf3198-bib-0014","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913074704400_ejhf3198-bib-0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026010913074704400_ejhf3198-bib-0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: Early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026010913074704400_ejhf3198-bib-0017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"key":"2026010913074704400_ejhf3198-bib-0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010283","article-title":"Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis\u2014A clinical feasibility study","volume":"13","author":"Steinhardt","year":"2024","journal-title":"J Clin Med"},{"key":"2026010913074704400_ejhf3198-bib-0019","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913074704400_ejhf3198-bib-0020","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0021","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0022","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: A post hoc analysis of the EMPEROR-Preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0023","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2026010913074704400_ejhf3198-bib-0024","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026010913074704400_ejhf3198-bib-0026","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-Reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913074704400_ejhf3198-bib-0027","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","article-title":"Association of dapagliflozin use with clinical outcomes and the introduction of uric acid-lowering therapy and colchicine in patients with heart failure with and without gout: A patient-level pooled meta-analysis of DAPA-HF and DELIVER","volume":"8","author":"Butt","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026010913074704400_ejhf3198-bib-0028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","article-title":"Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: Association with outcomes and the clinical phenotype","volume":"27","author":"Driggin","year":"2020","journal-title":"Amyloid"},{"key":"2026010913074704400_ejhf3198-bib-0029","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026010913074704400_ejhf3198-bib-0030","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913074704400_ejhf3198-bib-0032","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ejhf.3136","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved","volume":"26","author":"Rastogi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913074704400_ejhf3198-bib-0033","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.amjcard.2022.05.003","article-title":"Relation of body mass index to transthyretin cardiac amyloidosis particularly in Black and Hispanic patients (from the SCAN-MP study)","volume":"177","author":"Poterucha","year":"2022","journal-title":"Am J Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/938\/65514426\/eurjhf_26_4_938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/938\/65514426\/eurjhf_26_4_938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:41Z","timestamp":1767982181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/4\/938\/8328871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3198","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"2023-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}